ClinicalTrials.gg
CompletedNCT03496896TARGET-READUpdated Jan 26, 2023

Transition cAre inteRvention tarGeted to High-risk patiEnts To Reduce rEADmission

An interventional study of TARGET in Patient Readmission, sponsored by Insel Gruppe AG, University Hospital Bern. Completed at 4 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,393
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Hospital rehospitalizations within 30 days are frequent and represent a burden for the patients, but also for the entire health care system. This study evaluates the impact of an intervention targeted to high-risk medical patients in order to reduce their risk of rehospitalization. Half of the patients will receive a set of interventions before and after their hospital discharge, while the other half will receive usual care.

Read the detailed description

Background: Hospital readmissions within 30 days are frequent, with rates varying usually between 12 and 20%. Is it therefore recognized as important to improve the quality of the transition of care period in order to avoid as much as possible hospital readmissions. There are however still several gaps in current knowledges. First, most trials to reduce hospital readmission have been performed on specific patient populations such as patients with diabetes or heart failure, and therefore the findings may not be well generalizable to other high-risk population. Second, while some specific interventions have been showed to reduce readmission, these were complex and resources demanding, and no trial targeted these interventions to the patients who are most likely to benefit for better effectiveness, using a widely validated prediction tool, such as the "HOSPITAL" score. Finally, most studies tested unimodal interventions instead of more promising multimodal interventions.

Specific aim: the goal of this proposal is to evaluate the effect of a multimodal transitional care intervention prioritized to higher-risk medical patients on the composite of 30-day unplanned readmissions and death.

Methods: the investigators will conduct a multicenter randomized controlled trial in medical inpatients discharged home or nursing home, who are identified as having a higher risk for 30-day readmission. Risk of readmission will be predicted using the simplified HOSPITAL score, which includes 6 variables routinely available before hospital discharge and which has been previously validated in more than 200,000 patients across 6 countries in its original version, and in nearly 120,000 patients in its simplified version. Patients will be randomly assigned to the intervention group or usual care group. The primary outcome will be the first 30-day unplanned readmission or all-cause mortality. The primary analysis will be a comparison between two groups according to the intention-to-treat principle.

02

Conditions studied

  • Patient Readmission

Keywords

  • Randomized Controlled Trial
  • Patient readmission
  • Patient transfer
  • Health care utilization
  • Prognosis
  • Multimorbidity
  • Internal medicine
03

In context

Patient Acceptance of Health Care

308 studies on the registry are indexed under Patient Acceptance of Health Care; 53 are open to participants now.

This study's enrollment of 1,393 is above the median of 201 across 217 interventional studies indexed under Patient Acceptance of Health Care.

Browse Patient Acceptance of Health Care studies →

Lead sponsor

Insel Gruppe AG, University Hospital Bern is the lead sponsor of 741 studies on the registry; 179 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult Patients planned to be discharged home/nursing home from a medical department.
  • Hospital stay of at least 24 hours.
  • Patient at higher risk of 30-day readmission based on the simplified HOSPITAL score.

Exclusion criteria

Exclusion Criteria:

  • Previous enrolment in this trial.
  • Patient is not living in the country in the next 30 days.
  • No phone to be reached at.
  • Not speaking the local language.
  • Refusal to participate, or unable to give consent.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,393 participants (actual)

Study arms

  • Experimental
    "TARGET" intervention

    The intervention group will receive a standardized transition care intervention by a trained nurse composed of a pre-discharge component and 2 post-discharge follow-up phone calls 3 days and 14 days after discharge.

    Other: TARGET

  • No intervention
    Control

    The group control will receive usual care without additional intervention.

Interventions

  • OtherTARGET

    The pre-discharge component includes mainly patient information, medication reconciliation, patient education, planning of a first post-discharge primary care physician visit with a timely discharge summary sent to the primary care physician. Two follow-up phone calls are made by a nurse, at D3 and D14, and include the assessment of the general health condition, the verification of the follow-up care plan, a reinforcement of the patient education, and review with the patient of the medication list with assessment of potential adverse drug events.

06

What researchers measure

Primary outcomes

  1. 30-day unplanned readmission or death

    Number of patients who have a first unplanned readmission or die within 30 days after discharge (Composite endpoint).

    Time frame: 30 days after hospital discharge

Secondary outcomes

  1. First 30-day unplanned readmission

    Number of patients who have a first unplanned readmission (individual components of the primary composite outcome)

    Time frame: 30 days after hospital discharge

  2. 30-day mortality

    Number of patients who die (individual components of the primary composite outcome).

    Time frame: 30 days after hospital discharge

  3. Time to first unplanned readmission or death

    Number of days between hospital discharge and first unplanned readmission or death.

    Time frame: Within 30 days after hospital discharge

  4. Patient's perspective (satisfaction) on quality of transition of care between hospital and home

    Proportion of patients who are responding positively to all 3 items of the Three-Item Care Transition Measure (CTM-3)

    Time frame: 30 days after hospital discharge

  5. Post-discharge health care utilization 1

    Total number of readmission(s)

    Time frame: 30 days after hospital discharge

  6. Post-discharge health care utilization 2

    Total number of days of hospitalizations within 30 days

    Time frame: 30 days after hospital discharge

  7. Post-discharge health care utilization 3

    Number of emergency room visits

    Time frame: 30 days after hospital discharge

  8. Post-discharge health care utilization 4

    Number of primary care provider visits

    Time frame: 30 days after hospital discharge

  9. Main cause of readmission or death

    Proportion of most frequent main diagnosis for the readmission

    Time frame: 30 days after hospital discharge

  10. Costs of readmission

    Total costs of the rehospitalization in Swiss Francs (CHF)

    Time frame: 30 days after hospital discharge

07

Study locations

4 sites
  • Centre hospitalier Bienne
    Bienne, Bern 2502, Switzerland
  • Hôpital cantonal Fribourg
    Fribourg, 1708, Switzerland
  • Centre hospitalier universitaire vaudois (CHUV)
    Lausanne, 1005, Switzerland
  • Hôpital neuchâtelois
    Neuchâtel, 2000, Switzerland
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Feb 2020, 22 months.

Of 151 non-industry interventional studies with no phase under Patient Acceptance of Health Care, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's 22 months is above that.

Counting every sponsor, half of 154 studies reached it within 19 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2018
First posted
Apr 12, 2018
StartActual
Apr 3, 2018
Primary completionActual
Feb 15, 2020
CompletionActual
Feb 15, 2020
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03496896
Collaborators
Swiss National Science Foundation, University of Bern, Brigham and Women's Hospital
Responsible party
Sponsor
First posted
Apr 12, 2018
Start date
Apr 3, 2018
Primary completion
Feb 15, 2020
Completion
Feb 15, 2020
Last update
Jan 26, 2023

Study contacts

Jacques Donzé, MD, MSc
principal investigator · Bern University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion